CA1142083A - Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same - Google Patents

Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Info

Publication number
CA1142083A
CA1142083A CA000339541A CA339541A CA1142083A CA 1142083 A CA1142083 A CA 1142083A CA 000339541 A CA000339541 A CA 000339541A CA 339541 A CA339541 A CA 339541A CA 1142083 A CA1142083 A CA 1142083A
Authority
CA
Canada
Prior art keywords
membrane proteins
neisseria meningitidis
isolation
detergent
containing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000339541A
Other languages
English (en)
French (fr)
Inventor
Torsten B. Helting
Gerhard Guthohrlein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines GmbH
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Application granted granted Critical
Publication of CA1142083A publication Critical patent/CA1142083A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA000339541A 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same Expired CA1142083A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP2848965.8 1978-11-11
DE19782848965 DE2848965A1 (de) 1978-11-11 1978-11-11 Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine

Publications (1)

Publication Number Publication Date
CA1142083A true CA1142083A (en) 1983-03-01

Family

ID=6054405

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000339541A Expired CA1142083A (en) 1978-11-11 1979-11-09 Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same

Country Status (9)

Country Link
EP (1) EP0011243B1 (show.php)
JP (1) JPS5566519A (show.php)
AT (1) ATE857T1 (show.php)
AU (1) AU533386B2 (show.php)
CA (1) CA1142083A (show.php)
DE (2) DE2848965A1 (show.php)
DK (1) DK154841C (show.php)
ES (1) ES485715A1 (show.php)
IL (1) IL58673A (show.php)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317811A (en) 1980-09-11 1982-03-02 Merck & Co., Inc. Herpes simplex type 1 subunit vaccine
JPH074267B2 (ja) * 1982-12-02 1995-01-25 ザ ロツクフエラ− ユニバ−シテイ 免疫グロブリンa結合性抗体
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
ATE346609T1 (de) 1998-05-29 2006-12-15 Novartis Vaccines & Diagnostic Kombinierte meningitis b/c impfstoffe
DK2270173T3 (en) 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DK1248647T3 (da) 2000-01-17 2010-09-27 Novartis Vaccines & Diagnostic Ydre membranvesikel (OMV) vaccine omfattende N. meningitidis serogruppe B ydre membranproteiner
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2004014417A2 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7628995B2 (en) * 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2654706A1 (en) 2006-06-12 2007-12-21 Nathalie Devos Neisseria meningitidis lipooligosaccharide vaccine
DK2200642T3 (da) 2007-10-19 2012-07-16 Novartis Ag Meningococvaccinepræparater
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CA2747340A1 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP2440245B1 (en) 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphthyridine-containing vaccines
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為tlr活性調節劑之化合物及組合物
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012022669A2 (pt) 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
BR112012022896A2 (pt) 2010-03-18 2018-03-27 Novartis Ag vacinas adjuvantes para meningococos do sorogrupo b
CA2792938C (en) 2010-03-23 2018-07-31 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
RU2644340C2 (ru) 2012-06-14 2018-02-08 Новартис Аг Вакцины для менингококка серогруппы х
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
CN104602702B (zh) 2012-09-18 2021-08-27 葛兰素史密丝克莱恩生物有限公司 外膜囊泡
EA034954B1 (ru) 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
WO2018042017A2 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
JP7369690B2 (ja) 2017-09-08 2023-10-26 エヴェロ バイオサイエンシズ,インコーポレーテッド 細菌の細胞外小胞
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
EA202190914A1 (ru) 2018-11-06 2021-08-03 Глаксосмитклайн Байолоджикалс Са Иммуногенные композиции
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202115072D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408907B2 (en) 2009-12-15 2016-08-09 Glaxosmithkline Biologicals Sa Homogenous suspension of immunopotentiating compounds and uses thereof
US10046048B2 (en) 2009-12-15 2018-08-14 Glaxosmithkline Biologicals S.A. Homogenous suspension of immunopotentiating compounds and uses thereof
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus

Also Published As

Publication number Publication date
EP0011243A1 (de) 1980-05-28
JPS5566519A (en) 1980-05-20
ATE857T1 (de) 1982-04-15
AU533386B2 (en) 1983-11-24
IL58673A (en) 1983-02-23
DK475779A (da) 1980-05-12
DK154841B (da) 1988-12-27
DE2962526D1 (en) 1982-05-27
DK154841C (da) 1989-06-05
IL58673A0 (en) 1980-02-29
ES485715A1 (es) 1980-05-16
JPS6350332B2 (show.php) 1988-10-07
EP0011243B1 (de) 1982-04-14
DE2848965A1 (de) 1980-05-22
AU5268279A (en) 1980-05-15

Similar Documents

Publication Publication Date Title
CA1142083A (en) Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same
US4271147A (en) Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
CN102356089B (zh) 脑膜炎球菌fHBP多肽
AU2010310985B2 (en) Modified meningococcal fHBP polypeptides
EP2470204B1 (en) Hybrid polypeptides including meningococcal fhbp sequences
JP2911603B2 (ja) 新規な弱毒化シュードモナス・エルギノーザ株
CN102724988B (zh) 脑膜炎球菌fHBP多肽的表达
JPS61186400A (ja) 細菌由来中性多糖類と免疫原性タン白との安定な、共有結合された多糖―タンパク質結合体、該結合体の製造方法並びに該結合体を含む医薬組成物
JPH0819396A (ja) グラム−陰性球菌のリポオリゴ糖が除去された外膜蛋白質の製造および使用
EA034954B1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
CS244906B2 (en) Production method of antigen agent for limitation or prevention of tooth defects
EP0407037B1 (en) Process for removing bacterial endotoxin from gram-negative polysaccharides
CN106215183A (zh) 一种abc群脑膜炎球菌联合疫苗及其制备方法
CN105749264A (zh) 免疫活性组合物
EP0090660A2 (en) Neisseria gonorrhoeae vaccine
US6106842A (en) Extraction of cell-bound protein from bordetella
JPS5852227A (ja) 淋菌からの免疫原性複合体
RU2407792C1 (ru) СПОСОБ ПОЛУЧЕНИЯ IgAl-ПРОТЕАЗЫ ИЗ КУЛЬТУРЫ NEISSERIA MENINGITIDIS СЕРОГРУППЫ А И ИММУНОГЕННЫЙ ПРЕПАРАТ НА ЕЕ ОСНОВЕ
CN120754237B (zh) 含多价肺炎球菌多糖-蛋白结合物的免疫原性组合物及其制备方法和应用
KR810001317B1 (ko) 혼합백신의 제조방법
AU2015200160A1 (en) Modified meningococcal fHBP polypeptides
JPS59500615A (ja) ナイザ−淋菌ワクチン
JPS5946490B2 (ja) 抗アレルギ−剤及びその製法
AU2014250679A1 (en) Meningococcal fHBP polypeptides

Legal Events

Date Code Title Description
MKEX Expiry